Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 27, 2015 6:48 PM ET

Biotechnology

Company Overview of VBI Vaccines Inc

Company Overview

VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

222 Third Street

Suite 2241

Cambridge, MA 02142

United States

Founded in 2006

18 Employees

Phone:

617-830-3031

Fax:

888-391-2579

Key Executives for VBI Vaccines Inc

Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $350.0K
Chief Financial Officer
Age: 48
Total Annual Compensation: $198.0K
Senior Vice President of Research
Age: 43
Total Annual Compensation: $220.0K
Vice President of Formulation Development
Age: 51
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2013.

VBI Vaccines Inc Key Developments

VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM

VBI Vaccines Inc Presents at Noble Financial Capital Markets Eleventh Annual Investor Conference, Jan-20-2015 02:30 PM. Venue: Club Med, Sandpiper Bay, Florida, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.

VBI Vaccines Inc Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 12:45 PM

VBI Vaccines Inc Presents at Equities.com Small-Cap Stars Conference, Dec-18-2014 12:45 PM. Venue: NASDAQ MarketSite, New York, New York, United States. Speakers: Jeff Baxter, Chief Executive Officer, President and Director.

Andrews & Springer LLC Files Class Action Lawsuit on Behalf of Legacy Shareholders of VBI Vaccines, Inc

Andrews & Springer LLC announced that it has filed a securities class action lawsuit on behalf of legacy shareholders of Paulson Capital Corp. (now referred to as VBI Vaccines Inc.) who held shares on October 11, 2013 and were eligible to vote at the Company's Annual Meeting of Shareholders held on November 8, 2013. This lawsuit was filed in the United States District Court, Southern District of New York, Case No. 14-cv-9435. Paulson Capital Corp. was once a publicly-traded financial services holding company that operated through its sole subsidiary Paulson Investment Company. According to the lawsuit, PCC issued materially false and misleading information to investors. On October 18, 2013, the Company filed a Definitive Proxy Statement on Schedule 14A (the October Proxy Statement) with the U.S. Securities and Exchange Commission and solicited votes from shareholders necessary to approve a certain restructuring transaction. Among other things, the October Proxy Statement asked PCC shareholders who held shares as of October 11, 2013 to vote on a transaction that would, among other things, spin off certain legacy assets of PCC and PIC into a Liquidating Trust for the benefit of Legacy Shareholders. The October Proxy Statement set October 11, 2013 as the record date for a shareholder meeting that was scheduled to take place on November 8, 2013. PCC represented to Legacy Shareholders that the Trust Assets included, among other things, a 25% equity interest in PIC, underwriter warrants, trading and investment securities, cash, accounts receivable and an insurance policy on the life of Chester L.F. Paulson, the founder of PIC. Collectively, the Trust Assets were valued at approximately $16.6 million. Legacy Shareholders overwhelmingly voted in favor of the Restructuring Transaction and the formation of the Liquidating Trust at the meeting of shareholders held on November 8, 2013.

Similar Private Companies By Industry

Company Name Region
Lighthouse Biosciences, Inc. United States
Dominion Biosciences, Inc. United States
NellOne Therapeutics, Inc. United States
Abeome Corporation United States
MaxCyte, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
May 9, 2014
Paulson Capital (Delaware) Corp.
Private Placement
May 8, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VBI Vaccines Inc, please visit www.vbivaccines.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.